Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
NCT01226147 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2011-07-22
Summary
An open-label study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Lupus Nephritis
Conditions
Interventions
- DRUG
-
Tamibarotene
4mg/day for 24 weeks.
Sponsors & Collaborators
-
Kinki University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-09-30
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
Countries
- Japan
Study Locations
More Related Trials
-
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
NCT05688696 ·Status: RECRUITING ·Phase: PHASE2
-
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
NCT02453997 ·Status: COMPLETED
-
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
NCT04643470 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
NCT00371319 ·Status: COMPLETED ·Phase: PHASE4
-
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
NCT02435368 ·Status: UNKNOWN
-
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
NCT02770170 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)
NCT01449071 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus
NCT05930314 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
NCT07109986 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
NCT00429377 ·Status: COMPLETED ·Phase: PHASE3
-
Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
NCT03920059 ·Status: TERMINATED ·Phase: PHASE4
-
TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
NCT02711813 ·Status: TERMINATED ·Phase: PHASE2
-
Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis
NCT01042457 ·Status: COMPLETED ·Phase: PHASE3
-
Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
NCT00125307 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
NCT00298506 ·Status: COMPLETED ·Phase: NA
-
Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
NCT01773616 ·Status: TERMINATED ·Phase: PHASE3
-
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)
NCT01381536 ·Status: COMPLETED ·Phase: PHASE1
-
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
NCT00908986 ·Status: WITHDRAWN ·Phase: NA
-
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
NCT05504187 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
NCT00282347 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
NCT00709722 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
NCT00774943 ·Status: COMPLETED ·Phase: PHASE1
-
Etanercept for the Treatment of Lupus Nephritis
NCT00447265 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
NCT05856448 ·Status: COMPLETED ·Phase: PHASE2